Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Open-Label, Randomized, Single-Dose Study With Crossover Design to Investigate the Effect of Food on the Pharmacokinetics of Peposertib Tablet Formulation and to Investigate the Pharmacokinetics of Peposertib Administered as Oral Suspension of Disintegrated Tablets

Next Previous
X
Search
Trial Profile

Phase I, Open-Label, Randomized, Single-Dose Study With Crossover Design to Investigate the Effect of Food on the Pharmacokinetics of Peposertib Tablet Formulation and to Investigate the Pharmacokinetics of Peposertib Administered as Oral Suspension of Disintegrated Tablets

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peposertib (Primary) ; Peposertib (Primary)
  • Indications Glioblastoma; Neuroendocrine tumours; Rectal cancer; Small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Merck KGaA

    • Most Recent Events

    • 11 May 2021 Status changed from recruiting to completed.
    • 04 Feb 2021 Status changed from not yet recruiting to recruiting.
    • 13 Jan 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top